AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...

The AAV vector manufacturing market is mainly fueled by the expanding landscape of gene therapy research and development, as AAV vectors are extensively utilized for therapeutic gene delivery because ...

Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation (CDMO), and NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy, today announced ...

High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...

Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company focused on cardiovascular disease treatments, announced that it will present new data on its AAV manufacturing approach at the 28th ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy ...

AAVnerGene Inc. today announced the launch of AAVone2.1, the next-generation evolution of its proprietary AAVone single-plasmid AAV production ...